These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 9733451

  • 21. Management of "refractory" skin disease in patients with lupus erythematosus.
    Callen JP.
    Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):767-84. PubMed ID: 16150402
    [Abstract] [Full Text] [Related]

  • 22. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus.
    Carneiro JR, Sato EI.
    J Rheumatol; 1999 Jun; 26(6):1275-9. PubMed ID: 10381042
    [Abstract] [Full Text] [Related]

  • 23. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy.
    Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T.
    Br J Dermatol; 2007 Jun; 156(6):1321-7. PubMed ID: 17408395
    [Abstract] [Full Text] [Related]

  • 24. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative.
    Lampropoulos CE, Sangle S, Harrison P, Hughes GR, D'Cruz DP.
    Rheumatology (Oxford); 2004 Nov; 43(11):1383-5. PubMed ID: 15266063
    [Abstract] [Full Text] [Related]

  • 25. Smoking status and psychosocioeconomic outcomes of functional restoration in patients with chronic spinal disability.
    McGeary DD, Mayer TG, Gatchel RJ, Anagnostis C.
    Spine J; 2004 Nov; 4(2):170-5. PubMed ID: 15016394
    [Abstract] [Full Text] [Related]

  • 26. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy.
    Ordi-Ros J, Cortés F, Cucurull E, Mauri M, Buján S, Vilardell M.
    J Rheumatol; 2000 Jun; 27(6):1429-33. PubMed ID: 10852265
    [Abstract] [Full Text] [Related]

  • 27. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.
    Ibañez D, Gladman DD, Urowitz MB.
    J Rheumatol; 2005 May; 32(5):824-7. PubMed ID: 15868616
    [Abstract] [Full Text] [Related]

  • 28. Cutaneous lupus erythematosus: a personal approach to management.
    Callen JP.
    Australas J Dermatol; 2006 Feb; 47(1):13-27. PubMed ID: 16405478
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.
    Wenzel J, Brähler S, Bauer R, Bieber T, Tüting T.
    Br J Dermatol; 2005 Jul; 153(1):157-62. PubMed ID: 16029342
    [Abstract] [Full Text] [Related]

  • 30. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs.
    López P, Gómez J, Mozo L, Gutiérrez C, Suárez A.
    Arthritis Res Ther; 2006 Jul; 8(2):R42. PubMed ID: 16507146
    [Abstract] [Full Text] [Related]

  • 31. Smokers have less reductions in probing depth than non-smokers following nonsurgical periodontal therapy.
    Garcia RI.
    Evid Based Dent; 2005 Jul; 6(2):37-8. PubMed ID: 16208387
    [Abstract] [Full Text] [Related]

  • 32. [Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study].
    Lardet D, Martin S, Truchetet F, Cuny JF, Virion JM, Schmutz JL.
    Rev Med Interne; 2004 Nov; 25(11):786-91. PubMed ID: 15501347
    [Abstract] [Full Text] [Related]

  • 33. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
    Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE.
    Arthritis Rheum; 2004 Sep; 50(9):2858-68. PubMed ID: 15452837
    [Abstract] [Full Text] [Related]

  • 34. Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus.
    Boeckler P, Cosnes A, Francès C, Hedelin G, Lipsker D.
    Arch Dermatol; 2009 Sep; 145(9):1012-6. PubMed ID: 19770440
    [Abstract] [Full Text] [Related]

  • 35. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials.
    Gonzalez-Lopez L, Gamez-Nava JI, Jhangri G, Russell AS, Suarez-Almazor ME.
    J Rheumatol; 2000 Jan; 27(1):41-6. PubMed ID: 10648016
    [Abstract] [Full Text] [Related]

  • 36. Accrual of organ damage over time in patients with systemic lupus erythematosus.
    Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS.
    J Rheumatol; 2003 Sep; 30(9):1955-9. PubMed ID: 12966597
    [Abstract] [Full Text] [Related]

  • 37. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus.
    Zonana-Nacach A, Yañez P, Jiménez-Balderas FJ, Camargo-Coronel A.
    Lupus; 2007 Sep; 16(12):997-1000. PubMed ID: 18042596
    [Abstract] [Full Text] [Related]

  • 38. The efficacy of antimalarials in systemic lupus erythematosus.
    Nayak V, Esdaile JM.
    Lupus; 1996 Jun; 5 Suppl 1():S23-7. PubMed ID: 8803906
    [Abstract] [Full Text] [Related]

  • 39. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
    Cavazzana I, Sala R, Bazzani C, Ceribelli A, Zane C, Cattaneo R, Tincani A, Calzavara-Pinton PG, Franceschini F.
    Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
    [Abstract] [Full Text] [Related]

  • 40. A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus.
    Karlson EW, Liang MH, Eaton H, Huang J, Fitzgerald L, Rogers MP, Daltroy LH.
    Arthritis Rheum; 2004 Jun; 50(6):1832-41. PubMed ID: 15188360
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.